

Prescription Drug Program

Washington State Health Care Authority 1511 - 3rd Avenue, Suite 523 Seattle, WA 98101 www.rx.wa.gov

February 28, 2013

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority (Medicaid/Uniform Medical Plan) and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective May 1, 2013:

Estrogen – Oral reviewed 12/21/2011		Agency Coverage		
Ingredient Name	Label Name of Preferred Product	L&I	Medicaid	UMP
estradiol	estradiol tablet	No	Yes	Yes
estropipate	estropipate tablet	No	Yes	Yes
estrogens, esterified	Menest [®] tablet	No	Yes	Yes
The effect of this recon	nmendation is no change to the	PDL.		
Estrogen – Oral Combination		Agency Coverage		
Ingredient Name	Label Name of Preferred	L&I	Medicaid	UMP
	Product			
estradiol;	estradiol/ norethindrone	No	Yes	Yes
norethindrone acetate	acetate tablet			
	mimvey tablet	No	Yes	Yes
	nmendation is to make Activell	a® non-pr	referred on the PI	DL.
Estrogen - Transdermal		Agency Coverage		
Ingredient Name	Label Name of Preferred Product	L&I	Medicaid	UMP
The effect of this recon	nmendation is no change to the	PDL.		
Estrogen –Transdermal Combination		Agency Coverage		
Ingredient Name	Label Name of Preferred Product	L&I	Medicaid	UMP
The effect of this recon	nmendation is no change to the	PDL.		
Estrogen – Vaginal		Agency Coverage		
estradiol	Estring [®] ring	No	Yes	Yes
The effect of this recon Vagifem® non-preferre	nmendation is to make Estring®	preferred	on the PDL and	make



Prescription Drug Program

Washington State Health Care Authority 1511 - 3rd Avenue, Suite 523 Seattle, WA 98101 www.rx.wa.gov

Proton Pump Inhibitors reviewed 12/21/2011		Agency Coverage		
Ingredient Name	Label Name of Preferred	L&I	Medicaid	UMP
	Product			
Lansoprazole	Prevacid Solutab®	No	For children	No
			& unable to	
			swallow only	
omeprazole	omeprazole capsule-	Yes	Yes	No
	delayed release/tablet-			
	enteric coated			
omeprazole	omeprazole magnesium	Yes	Yes	No
magnesium	capsule-delayed release			
pantoprazole sodium	pantoprazole sodium	Yes	Yes	No
sesquihydrate	tablet-enteric coated			
	Protonix Pack®	No	For children	No
			& unable to	
			swallow only	

The effect of this recommendation is to make Prilosec OTC® and omeprazole/sodium bicarbonate non-preferred on the PDL and make Protonix Pack® and pantoprazole sodium preferred on the PDL.

Overactive Bladder (OAB) Update:

The agencies are withdrawing the changes to the OAB drug class on the Washington State Preferred Drug List (PDL) announced on January 25, 2013. There will be no changes to the OAB class effective March 1, 2013 and the class will be reviewed again in August 2013.

Each agency will use the common PDL according to its benefit structure. You may view the current PDL at: http://www.rx.wa.gov/documents/washingtonpdl.pdf .

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (206) 521-2029 or by email at leta.evaskus@hca.wa.gov.

Sincerely.

Director, Prescription Drug Program Washington State Health Care Authority